<bill session="116" type="s" number="977" updated="2020-02-10T17:07:03Z">
  <state datetime="2019-04-01">REFERRED</state>
  <status>
    <introduced datetime="2019-04-01"/>
  </status>
  <introduced datetime="2019-04-01"/>
  <titles>
    <title type="official" as="introduced">A bill to address the high cost of prescription drugs.</title>
    <title type="short" as="introduced">Transparent Drug Pricing Act of 2019</title>
    <title type="short" as="introduced">Transparent Drug Pricing Act of 2019</title>
    <title type="display">Transparent Drug Pricing Act of 2019</title>
  </titles>
  <sponsor bioguide_id="S001217"/>
  <cosponsors>
    <cosponsor bioguide_id="H001089" joined="2019-04-01"/>
  </cosponsors>
  <actions>
    <action datetime="2019-04-01">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-04-01" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Asia"/>
    <term name="Canada"/>
    <term name="Consumer affairs"/>
    <term name="Employee benefits and pensions"/>
    <term name="Europe"/>
    <term name="France"/>
    <term name="Germany"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Inflation and prices"/>
    <term name="Japan"/>
    <term name="Prescription drugs"/>
    <term name="Retail and wholesale trades"/>
    <term name="United Kingdom"/>
  </subjects>
  <amendments/>
  <summary date="2019-04-01T04:00:00Z" status="Introduced in Senate">Transparent Drug Pricing Act of 2019

This bill establishes several requirements relating to the prices of prescription drugs.

For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period.

The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.</summary>
  <committee-reports/>
</bill>
